Insulin Resistance Pipeline Therapeutics Development Market Report in H2 2017

PUNE, India, July 24, 2017 /PRNewswire-iReach/ -- RnRMarketResearch.com adds "Insulin Resistance Pipeline Review, H2 2017" to its store. The provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).

Insulin Resistance pipeline Companies Involved in Therapeutics Development are Amgen Inc, AusBio Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hadasit Medical Research Services & Development Ltd, Pfizer Inc, Prometheon Pharma LLC, Sanofi.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body's own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Order a copy of this research report athttp://www.rnrmarketresearch.com/contacts/purchase?rname=1141794 .

Insulin Resistance Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

List of Figures
Number of Products under Development for Insulin Resistance, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Other Report:

Hyperalgesia Pipeline Review, H2 2017: The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Companies are Cara Therapeutics Inc and Novartis AG.

 About Us:

RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Media Contact:Ritesh Tiwari, RnRMarketResearch.com, + 1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research